發(fā)布時間：2019-08-15 17:11

【摘要】：目的觀察卵巢癌(OC)患者腫瘤浸潤淋巴細胞(TILs)的抗腫瘤活性。方法采用聯(lián)合酶消化分離并提純OC組織中的TILs和OC細胞,以IL-2體外誘導(dǎo)活化擴增TILs�；罨凹盎罨�14天,采用流式細胞儀檢測TILs免疫表型(CD+3、CD+4、CD+8、CD+4/CD+8);活化前及活化第3、7、14天,采用MTT法檢測TILs對自體OC細胞、人白血病細胞株K562、人B細胞淋巴瘤細胞株Raji的殺傷活力;收集經(jīng)活化第14天TILs作用前后的OC細胞培養(yǎng)上清液,ELISA法檢測腫瘤分子標(biāo)志物CA-125、CA-153、血管內(nèi)皮生長因子(VEGF)、基質(zhì)金屬蛋白酶9(MMP-9)。結(jié)果與活化前比較,活化第14天TILs中CD+3、CD+4、CD+8細胞比例增加,CD+4/CD+8細胞比值降低;隨著活化時間延長,TILs對三種靶細胞的殺傷率增高(P均0.05),且對OC細胞的殺傷率高于其余2種細胞(P均0.05);與處理前相比較,活化第14天TILs作用的OC細胞培養(yǎng)上清液中CA-125、VEGF、MMP-9水平均顯著降低(P均0.05)。結(jié)論卵巢癌患者的TILs具有抗腫瘤活性,低濃度IL-2可增強其特異性和非特異性抗瘤活性。
[Abstract]:Objective to observe the antitumor activity of tumor infiltrating lymphocytes (TILs) in patients with ovarian cancer (OC). Methods TILs and OC cells in OC tissue were digested and purified by combined enzyme digestion and purification. TILs. was activated and amplified by IL-2 in vitro. The immunophenotypes of TILs (CD 3, CD 4, CD 8, CD 4/CD 8) were detected by flow cytometry before activation and 14 days after activation, and the killing activity of TILs against autologous OC cells, human leukemia cell line K562 and human B cell lymphoma cell line Raji was detected by MTT assay before activation and on the 3rd, 7th and 14th day of activation. The culture media of OC cells before and after activation of TILs on the 14th day were collected and the tumor molecular marker CA-125,CA-153, vascular endothelial growth factor (VEGF), matrix metalloprotease 9 (MMP-9) was detected by ELISA assay. Results on the 14th day after activation, the proportion of CD 3, CD 4, CD 8 cells and the ratio of CD 4/CD 8 cells in TILs increased, and the killing rate of TILs to three kinds of target cells increased with the prolongation of activation time, and the killing rate to OC cells was higher than that of the other two kinds of cells. Compared with those before treatment, the level of CA-125,VEGF,MMP-9 in the culture medium of OC cells treated with TILs on the 14th day was significantly decreased (P < 0.05). Conclusion TILs has antitumor activity in patients with ovarian cancer. Low concentration of IL-2 can enhance its specific and nonspecific antitumor activity.
【作者單位】： 南方醫(yī)科大學(xué)南方醫(yī)院;南方醫(yī)科大學(xué)第三附屬醫(yī)院;
【基金】：廣東省科技計劃資助項目(2011B031800042)
【分類號】：R737.31

【參考文獻】

相關(guān)期刊論文 前1條

1 王玉玲;TIL細胞聯(lián)合IL-2腹腔注射治療卵巢癌腹水12例[J];山東醫(yī)藥;2002年24期

【共引文獻】

相關(guān)期刊論文 前5條

1 Alan D Guerrero;Judy S Moyes;Laurence JN Cooper;;The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors[J];Chinese Journal of Cancer;2014年09期

2 高佃軍;孫鵬;李江松;王淑芳;柳港;;膀胱移行細胞癌組織中TIL反應(yīng)及其形態(tài)學(xué)觀察[J];山東醫(yī)藥;2008年08期

3 李坤,龍鳳宜;白細胞介素-2在卵巢癌免疫治療中的應(yīng)用[J];右江民族醫(yī)學(xué)院學(xué)報;2005年04期

4 何建明;黃湛;吳家豪;黃偉;胡可錦;;CD8~+腫瘤浸潤淋巴細胞與乳腺癌預(yù)后的關(guān)系[J];中國普通外科雜志;2013年11期

5 崔o，

本文編號：2527120